- Gujarat Themis Biosyn Limited will acquire 100% equity in Japan-based MicroBiopharm Japan Co., Ltd. in a deal valued at approximately Rs. 1,300 crore.
- The acquisition is intended to expand GTBL’s capabilities across fermentation, biologics, precision fermentation, and CDMO services.
Gujarat Themis Biosyn Limited (GTBL) has signed a definitive agreement to acquire 100% equity in MicroBiopharm Japan Co., Ltd. (MBJ) from funds managed by T Capital Partners Co., Ltd. The transaction, valued at approximately Rs. 1,300 crore, will be executed through GTBL’s wholly owned Japanese subsidiary, Themis Biosyn Japan Limited.
The acquisition will be completed through a special purpose vehicle to be incorporated in Japan and is expected to close during Q2FY27, subject to customary approvals and closing conditions. GTBL stated that the transaction forms part of its strategy to expand from a fermentation-focused intermediates business into a technology-driven CDMO platform spanning precision fermentation, biotechnology, and advanced pharmaceutical manufacturing.
MBJ is a Japanese pharmaceutical and biotechnology company with more than 60 years of experience in microbial research, fermentation, and pharmaceutical manufacturing. The company manufactures proprietary pharmaceuticals in oncology, immunosuppressants, antibiotics, and peptides, while also providing end-to-end CDMO and contract manufacturing services across small molecules and biologics. According to GTBL, MBJ generated estimated FY26 revenue of JPY 9.5 billion.
“This acquisition marks a strategic step in GTBL’s evolution toward a next-generation, discovery-led CDMO platform. MBJ’s differentiated fermentation and biotechnology capabilities, combined with its strong regulatory track record and scalable infrastructure, significantly enhance our ability to serve global customers across advanced and emerging therapeutic modalities.”
Dr. Sachin Patel, Managing Director of GTBL
GTBL stated that the acquisition consideration of approximately JPY 21.5 billion will be funded through a mix of debt and equity. The company added that the transaction is expected to strengthen its global pharmaceutical manufacturing and services business through expanded fermentation, biologics, and recombinant protein capabilities.
